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Abstract
Longitudinal imaging biomarkers are invaluable for understanding the course of neu-
rodegeneration, promising the ability to track disease progression and to detect disease
earlier than cross-sectional biomarkers. To properly realize their potential, biomarker tra-
jectory models must be robust to both under-sampling and measurement errors and
should be able to integrate multi-modal information to improve trajectory inference and
prediction. Here we present a parametric Bayesian multi-task learning based approach to
modeling univariate trajectories across subjects that addresses these criteria. Our
approach learns multiple subjects' trajectories within a single model that allows for differ-
ent types of information sharing, that is, coupling, across subjects. It optimizes a combina-
tion of uncoupled, fully coupled and kernel coupled models. Kernel-based coupling allows
linking subjects' trajectories based on one or more biomarker measures. We demonstrate
this using Alzheimer's Disease Neuroimaging Initiative (ADNI) data, where we model lon-
gitudinal trajectories of MRI-derived cortical volumes in neurodegeneration, with coupling
based on APOE genotype, cerebrospinal fluid (CSF) and amyloid PET-based biomarkers.
In addition to detecting established disease effects, we detect disease related changes
within the insula that have not received much attention within the literature. Due to its
sensitivity in detecting disease effects, its competitive predictive performance and its abil-
ity to learn the optimal parameter covariance from data rather than choosing a specific
set of random and fixed effects a priori, we propose that our model can be used in place
of or in addition to linear mixed effects models when modeling biomarker trajectories. A
software implementation of the method is publicly available.
K E YWORD S
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1 | INTRODUCTION
Despite their value in characterizing the course of neurodegeneration
(Freeborough & Fox, 1997; Smith, De Stefano, Jenkinson, &
†Data used in preparation of this article were obtained from the Alzheimer's Disease
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ADNI_Acknowledgement_List.pdf.
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Matthews, 2001), repeated measures over time (i.e., longitudinal data)
in neuroimaging are often limited to a baseline measurement and a
few follow-up time-points per subject. This is primarily due to the
costs and complexities of collecting such data. Consequently, within-
subject trajectory models of regions of interest (ROIs) or clinical measures
that are based on such limited data may not be robust to measurement
errors from image acquisition or post-processing. Such noise may lead
to poor inferences of true underlying trajectory parameters and poor
predictions of future values, diminishing the value of trajectory based
biomarkers (Curran, Obeidat, & Losardo, 2010). An additional problem
is a limit to the flexibility of the models that can be estimated: with
two time-points one can only estimate a linear model, with three only
a quadratic, and so on.
There has been growing interest in methods that efficiently use lon-
gitudinal neuroimaging data; e.g., Telzer et al., (Telzer et al., 2018) provide
an overview related to fMRI analysis. By far themost popular approaches
are based on mixed effect modeling, which combines fixed effects, that
is, pooling subjects' data to create an average trajectory for all subjects,
with random effects, that is, individualizing models about the average
trajectory. The mixed effects modeling approach is well suited to both
balanced (fixed number of samples, fixed time interval between samples)
and unbalanced (varying samples or time intervals) longitudinal designs,
allowing for separate analysis of between and within subject variability
(Fitzmaurice, Laird, & Ware, 2011; Laird & Ware, 1982). Bernal-Rusiel
et al. (2013) and Guillaume, Hua, Thompson, Waldorp, and Nichols
(2014) provide overviews of linear mixed effects (LME) models within
neuroimaging and apply them to Alzheimer's disease (AD).
Features from longitudinal measurements remove inter-individual
differences and thus make for better descriptions of disease progres-
sion. Recent models of disease progression have integrated both cross-
sectional and longitudinal information to estimate discrete or continuous
disease stages for individuals (Donohue et al., 2014; Fonteijn et al.,
2012; Jedynak et al., 2012; Lorenzi et al., 2017; Schiratti, Allassonnière,
Colliot, & Durrleman, 2017; Young et al., 2014). They have been
inspired by, and seek to quantify the hypothetical models of disease
progression proposed by neurodegenerative disease researchers
(Buckner et al., 2005; Jack et al., 2010). Oxtoby and Alexander ( 2017)
provide an overview of the methods within this emerging field. While
the purpose of disease progression modeling is to estimate disease stage
and find group-level (typically monotonic) trajectories for each bio-
marker, this procedure can be thought of as a form of coupling of bio-
marker trajectories across subjects. However, most of these models are
not explicitly setup to couple subjects' trajectories within each bio-
marker (e.g., a brain structural ROI) based on other biomarkers' informa-
tion (e.g., genetic risk or brain amyloid deposition). As such these models
may not fully capitalize on valuable multi-modal information that may
improve trajectory estimates within each biomarker.
Multi-kernel learning (MKL) presents an approach to combining
multiple biomarker similarity measures. It has been previously applied
to neuroimage-based pattern recognition and machine learning to dis-
criminate disease (Hinrichs, Singh, Xu, & Johnson, 2011; Zhang, Wang,
Zhou, Yuan, & Shen, 2011). Young et al. (2013) applied a Bayesian
MKL approach to AD discrimination, which avoided the need for
costly cross-validation when tuning the kernel weightings. In addition
to a more efficient means of tuning such hyperparameters, Bayesian
modeling also provides a principled approach to incorporating prior
information, comparing models, making probabilistic predictions, and
inferring distributions over parameters (Gelman et al., 2013). It has
been applied in many contexts within neuroimaging (Woolrich, 2012)
and more specifically in both parametric and nonparametric trajectory
models (Lorenzi, Ziegler, Alexander, & Ourselin, 2015; Ziegler, Penny,
Ridgway, Ourselin, & Friston, 2015).
In this article, we develop an approach that realizes the benefits of
MKL within a Bayesian trajectory model rather than a disease classifi-
cation model. To do so we use multi-task learning, which aims to learn
multiple related tasks simultaneously, sharing information across
tasks. Bayesian MTL was previously applied in neuroimaging within
the context of multi-subject fMRI analysis (Marquand, Brammer,
Williams, & Doyle, 2014; Marquand, Brammer, et al. 2014) based on
the method proposed by Bonilla et al. (2008). Bayesian MTL has also
been applied to imaging genetics via a hierarchical Bayesian model
that encourages both individual and group sparsity (Greenlaw, Szefer,
Graham, Lesperance, & Nathoo, 2017; Nathoo, Greenlaw, &
Lesperance, 2016). Here we set the learning of each subject's bio-
marker trajectory as a task and apply MTL to share information across
subjects. We develop a parametric extension of Marquand et al.'s
approach, a joint Bayesian linear regression that allows for full cou-
pling across all subjects along with coupling based on biomarker simi-
larity, so that subjects with similar measures in one biomarker may
have more similar trajectories in another. Furthermore, we use MKL
to couple trajectories within a biomarker based on an optimal balance
of multiple other biomarkers' information. We compare our approach,
which learns the optimal parameter covariance from data to standard
LME modeling, where the parameter covariance structure depends on
the a priori choice of random and fixed effects.
This article (a) contributes a parametric model that learns a separate
trajectory for each subject while allowing for information-sharing across
subjects and the integration of multi-modal information during model
training, resulting in better predictions, and inferences; (b) performs sim-
ulations to validate the model and understand its properties; (c) applies
the model to clinical neuroimaging data, modeling cortical region of inter-
est (ROI) trajectories in neurodegeneration using various biomarkers for
coupling and (d) interprets and discusses the results.
2 | METHODOLOGY
2.1 | Model: Parametric Bayesian MTL
We present a univariate model of the temporal trajectory of a scalar
variable (e.g., values of an ROI or a clinical measure) across multiple
subjects. We set the learning of each subject's trajectory as a task and
use MTL to share information across subjects to better learn all sub-
jects' trajectories as a single, coupled model. Empirical Bayes allows us
to automatically tune the degree and type of coupling across subjects
using hyperparameters that control the overall covariance structure of
the parameters being learned.
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We start by specifying a single, large model for all n subjects' tra-
jectories, stacking the longitudinal observations of all subjects into the
vector y= y01    y0n
 0
, where yi is an mi×1 vector of observations for
the ith subject. In total, there are m=
Pn
i = 1mi observations across
subjects, so that y is a m×1 vector. To model these trajectories, we
can fit polynomial functions of time (e.g., age) using the following
model structure:
y=Xw+ ε=
X1
. .
.
Xn
2
664
3
775
w1
..
.
wn
2
664
3
775+ ε ð1Þ
where the overall design matrix X is block diagonal for a chosen poly-
nomial model of order p, with zeros in the off-diagonal entries. Defin-
ing d = p + 1, we have block Xi as the mi × d design matrix for subject
i having mi observations at times ti1,…, timi :
Xi =
1 ti1 t
p
i1
1 ti2 t
p
i2
..
. ..
. . .
. ..
.
1 timi    tpimi
2
666664
3
777775 ð2Þ
and w is an nd × 1 vector of parameters across subjects. If we
assume additive Gaussian noise ε~N(0, β−1Im) we can solve the
general linear model (GLM) formed by Equation (1) via ordinary
least squares (OLS) regression, finding a set of parameters w1, … ,
wn that describe the subjects' temporal trajectories. Each wi is a
d × 1 vector containing the trajectory parameters for subject i. In
the case of linear models wi is 2 × 1 and contains an intercept
and a slope term.
OLS regression is a simple and widely used means of model-
ing trajectories models for each subject. However, it assumes an
independent model for each subject, thereby ignoring the similar-
ity in other subjects' trajectories that may greatly improve both
prediction and parameter inference. Using a Bayesian approach,
we propose to overcome this problem by placing a prior proba-
bility distribution over these parameters. The form of the prior
we propose is:
p wð Þ=N 0,Σprior
  ð3Þ
Σprior = α1Ind +
Xd
i =1
Σci|{z}
inter−subject
 Mii|{z}
intra−subject
ð4Þ
Σci = αi1In + αi21n +
Xk
j = 1
αi j + 2ð ÞKj ð5Þ
where Mii is defined below and Σprior is of size nd × nd. The first term in
Equation (4), with weight α1, allows for a diagonal (i.e., independent)
covariance structure in the parameters1 and ensures the matrix is positive
definite. The second term is a sum of d Kronecker products. When fitting
linear models (i.e., polynomial models of degree one, as we will do
throughout this article), there are two such products: one for the 0th order
parameters (i.e., intercepts), the other for the first order parameters
(i.e., slopes or rates of change). In each case, we take the Kronecker prod-
uct of an inter-subject (coupling) matrix and an intra-subject matrix to form
part of the overall covariance matrix. Each Σci is an n × n matrix parame-
trized to allow for fully independent parameters (αi1In term, where In is an
n-dimensional identity matrix), fully coupled parameters (αi21n term, where
1n is an n-dimensional matrix of ones) and coupling based on the set of k
biomarker based kernels (the Kj’s, each an n-dimensional positive definite
matrix). The form of these biomarker kernels is detailed later in this paper.
As a result, each Σci contains at least k + 2 hyperparameters2 and overall
there are at least d(k + 2) covariance-related hyperparameters. It is impor-
tant to bear in mind the distinction between the hyperparameters (the α's)
used to control coupling among subjects and the parameters of individuals'
trajectory models (thewi’s stacked withinw).
The intra-subject matrix Mii describes how the trajectory parame-
ters within each subject's model are related to each other. We have
chosen each Mii to be a d × d indicator matrix equal to one on the i
th
diagonal element and zero elsewhere, so that there is no information
sharing between different parameter types (e.g., between intercepts
and slopes) within and across subjects. This prior structure allows us
to learn the inter-subject coupling separately for each parameter type,
giving the model a great deal of flexibility.
Note that simpler parametrizations of the covariance matrix are
possible. For instance, choosing Σprior = Σc  Id with Id the d × d iden-
tity matrix and Σc = α1In + α21n is closest to the form used in Mar-
quand et al. Using instead Σc = α1In + α21n +
Pk
j = 1α j + 2ð ÞKj implements
MKL. Both variations use fewer hyperparameters than our proposed
parametrization. However, these simpler models tie the coupling of
parameters types (e.g., intercepts and slopes) together and as such
may be more prone to inducing spurious coupling in one set of param-
eters while capturing true coupling in another (e.g., spuriously cou-
pling intercepts along with slopes). This may, in turn, lead to the
increased false positive group differences in subjects' parameters.
This prior structure differs from that used in hierarchical Bayesian
modeling, where individuals' first level parameter prior means are
specified as linear combinations of second level parameters that may
include covariates and grouping variables that also have prior distribu-
tions. In contrast, we assume a zero-mean prior on individuals' param-
eters and incorporate covariates via kernels within each Σci. Kernels
allow for nonlinear similarity measures between covariates, adding
modeling flexibility not present in linear hierarchical models. Hierar-
chical models, in contrast, offer a well-developed framework for
modeling fixed and random effects. The two approaches are not
mutually exclusive: it is possible to combine them, though for the sake
of simplicity we leave this as a topic for future work.
1In practice, we include an additional diagonal term εInd, with ε set to 10
−6 throughout, that
aids numerical stability when inverting Σprior.
2There may be more hyperparameters if the kernels themselves contain tuneable parameters.
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Finally, we choose the likelihood term, that is, the data observa-
tion model, to resemble the GLM from Equation (1), setting
p yð jX,wÞ=N yð jXw,β−1ImÞ ð6Þ
with X andw defined as before. We allow the model to learn the (inverse)
measurement noise level β within the likelihood as an additional hyper-
parameter. With the prior and likelihood thus specified, we can use Bayes'
rule to update our beliefs on the parameter distribution given some
observed data (i.e., find the posterior distribution). In this case as we have
a Gaussian prior and a Gaussian likelihood the posterior is also Gaussian
and has the following closed-form solution (Bishop, 2007):
p wjX,y,α,βð Þ=N wj w,Σpostð Þ ð7Þ
Σpost = Σ αð Þprior −1 + βXTX
 −1
ð8Þ
w= βΣpostXTy ð9Þ
where we have collected the covariance prior's hyperparameters into
the vector α and have made the dependence of the prior covariance
on these parameters explicit using the notation Σ(α)prior.
To estimate optimal values for α and β, we take the empirical Bayesian
approach described in Huertas et al. (2017) and Marquand, Brammer,
et al. (2014a) finding the α and β that maximize the marginal likelihood of
the observed data under our assumed model structure. With the prior as
in Equations (3)–(5) and the likelihood as in Equation (6) the log marginal
likelihood becomes:
log p yjα,βð Þ= −m
2
log 2πð Þ+ m
2
log βð Þ− 1
2
log Σ αð Þprior
 − 1
2
log Aj j
−
1
2
mTΣ αð Þ−1priorm−
β
2
y−Xmð ÞT y−Xmð Þ
where A=Σ αð Þ−1prior + βXTX and m= βA−1XTy. We used minimize, a con-
jugate gradients optimizer available within the gpml toolbox
(Rasmussen & Nickisch, 2010), which uses partial derivatives of the
marginal likelihood with respect to each of the hyperparameters. We
optimized these variables in the log domain to ensure positivity (see
Appendix for further details).
In this article we predict the biomarker value at each subject's
mean baseline and final follow-up ages, taking the probabilistic
approach of integrating over all possible posterior model parameters.
With the Gaussian posterior as in Equations (7)–(9) and the Gaussian
likelihood p(y*| X*,w) = N (y* |X*w, β−1Im) of observing predictions y*
given input X*, the predictive distribution that results from integration
has a closed form solution (Rasmussen, 2006):
p y*jX*,Xð Þ=N X* w,β−1I+X*A−1XT*
 
ð10Þ
where A=Σ αð Þ−1prior + βXTX and X* is an n× nd design matrix with a
row encoding either the mean baseline age or final sample age in this
case (or 2n×nd to predict both at once). In general, we can predict an
arbitrary number of time-points per subject by modifying X*
accordingly.
For all models, we standardize (i.e., z-score) the training data
across all subjects (the longitudinal observations y and each noncon-
stant column of the design matrix X) as well as the out-of-sample test-
ing data (X*, using the means and standard deviations from X) during
model building and prediction. This ensures that all trajectories are
modeled on a similar scale, which aids numerical stability when opti-
mizing the hyperparameters. We rescale both the predictions and the
estimated parameters back to their original dimensions for subsequent
analysis (e.g., estimating annualized rates of change and group differ-
ences in parameters). With higher order models, the columns of X
may be highly correlated, leading to unstable variance estimates. In
such cases, one may orthogonalize the columns prior to fitting the
model.
We use the log Bayes factor, a ratio of the logarithm of model evi-
dences (i.e., marginal likelihoods) to compare biomarker-information
based coupling to random-information based coupling. Log Bayes fac-
tors are a principled way of comparing Bayesian models, under the
assumption that each model has the same prior probability (Penny,
2012; Penny, Stephan, Mechelli, & Friston, 2004).
2.2 | Software: Model and figures
A MATLAB implementation of our method is available at https://github.
com/LeonAksman/bayes-mtl-traj. The brain images in Figures 4–6, S8,
S9, and S11 were produced via a command-line image render and snap-
shot tool, available at https://github.com/LeonAksman/vtkSnap.
2.3 | Simulations: Data generation
We created a simulation of subjects' trajectories that allowed us to com-
pare several versions of our proposed model along with a baseline model.
We simulated two scenarios: (a) linear trajectories with intercept variation:
group differences in intercept with fixed slope and (ii) linear trajectories
with slope variation: group differences in slope with fixed intercept. In both
cases, we simulated 200 subjects' trajectories at each simulation run. To
simulate intercept variation, for a given subject i we randomly selected an
intercept wi0 from the set {−10, −8, −6, −4, −2} and a fixed slope of
wi1 = − 1, and then randomly selected an initial measurement time ti1
between 0 and 10. We then generated three simulated samples with fixed
time intervals: y(ti1)= wi0 + wi1ti1 + εi1 = wi0 − ti1 + εi1, y(ti2 = ti1 + 0.05)
= wi0 − ti1 − 0.05 + εi2 and y(ti3 = ti1 + 0.10) = wi0 − ti1 − 0.10 + εi3,
where εi1, εi2, εi3 are three independent measurement errors, each drawn
from N(0, σm). We simulated four different levels of measurement noise,
σm = 1, 2, 4, 8. For each noise level, wemade 30 simulation runs and evalu-
ated nine different models (described below) on each run.We used the first
two samples of each subject (ti1, ti2 for subject i) to train each model and
the third sample (ti3 for subject i) to evaluate out-of-sample prediction
accuracy. The top row of Figure 1 provides an example of one simulation
run for 200 subjects at each noise level.
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To simulate slope variation, for a given subject i we randomly
selected a slope wi1 from the set {−1.0, −1.5, −2.0, −2.5, −3.0} and a
fixed intercept of wi1 = 0. We randomly selected ti1 as before and
generated y(ti1), y(ti2 = ti1 + 0.05), and y(ti3 = ti1 + 0.10) with measure-
ment errors εi1, εi2, εi3 drawn from N(0, σm). We used the same four
measurement noise levels and again made 30 simulation runs,
TABLE 1 Models fit at each simulation run
Model Purpose Kernel Covariance prior # Cov. Hyper's
random Allow both slope and intercept
coupling via random biomarker
K(r)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K rð ÞSE
 Mii 9
linear both Allow both slope and intercept
coupling via true biomarker
K(b)linear α1I2n +
P2
i = 1 αi1In + αi21n + αi3K bð Þlinear
 Mii 7
Gaussian both Allow both slope and intercept
coupling via true biomarker
K(b)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K bð ÞSE
 Mii 9
linear int Allow intercept coupling via true biomarker K(b)linear α1I2n + α11In + α121n + α13K bð Þlinear
 M11
+ α21In + α221nð ÞM22
6
Gaussian int Allow intercept coupling via
true biomarker
K(b)SE α1I2n + α11In + α121n + α13K bð ÞSE
 M11
+ α21In + α221nð ÞM22
7
linear slope Allow slope coupling via
true biomarker
K(b)linear α1I2n + α11In + α121nð ÞM11
+ α21In + α221n + α23K bð Þlinear
 M22
6
Gaussian slope Allow slope coupling via
true biomarker
K(b)SE α1I2n + α11In + α121nð ÞM11
+ α21In + α221n + α23K bð ÞSE
 M22
7
plain No biomarker based coupling None α1I2n + α11In + α121nð ÞM11
+ α21In + α221nð ÞM22
5
OLS No coupling None α1I2n, α1 ! ∞ 0
Note. Last column contains number of hyperparameters in given covariance prior.
F IGURE 1 Top row: One run of the simulation of 200 subjects' longitudinal samples with group differences in intercept at four different
measurement noise (σm) levels. Bottom row: The same with group differences in slope. Each subject has three samples, with trajectory parameters
chosen from among five gradations of intercept (top row) or slope (bottom row), indicated by different colors [Color figure can be viewed at
wileyonlinelibrary.com]
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generating 200 simulated subjects' trajectories for each noise level.
We evaluated the same nine models using the first two samples of
each subject for training and the third for prediction. The bottom row of
Figure 1 provides an example of one simulation run at each noise level.
2.4 | Simulations: Model building
We investigated how different variations of the model, with and
without biomarker-kernel-based coupling (i.e., via the Kj matrices
described above), performed under the two parameter variation sce-
narios and the four measurement noise levels. We created a 200 × 1
biomarker vector b as a noisy measure of the group difference in the
parameters, so that the ith element of b was bi = wi0 + εi under inter-
cept variation and bi = wi1 + εi under slope variation, with εi drawn
from N(0, 1) in both cases.3 Using this biomarker, we compared
two commonly used similarity matrices: (a) a rank-one approximation
K(b)linear = bb
T (the outer product of b with itself); and (b) a squared
exponential (SE) kernel (also referred to as a Gaussian radial basis
function kernel) K(b)SE, with kij = exp(−σSEkbi − bjk2) in the ith row and
jth column, where we make the dependence of these matrices on the
input explicit. The term σSE > 0 is a parameter that gives the kernel
additional scaling flexibility. It is also possible to encode categorical
(i.e., group) membership via a binary similarity matrices rather than an
SE kernel, with one indicating two subjects belong to the same class
and zero otherwise.
When using SE kernels, we treated the σSE term as a covariance
prior hyperparameter (in addition to the α's in Equations [4] and [5]).
We formed six different models using these two kernels: “linear both”
and “Gaussian both” had covariance prior structure as in Equa-
tions (4) and (5), parameterizing full independence, full coupling and
kernel-based coupling in both the intercept and slope parameters. The
“linear int” and “Gaussian int” models restricted kernel-based coupling
to the intercepts: referring to Equations (4) and (5) and assuming one
coupling kernel K1, this means we allow a K1 term in Σc1 but not in
Σc2. The “linear slope” and “Gaussian slope,” in contrast, restricted
kernel-based coupling to the slopes, allowing a K1 term in Σc2 but not
in Σc1. These latter four models allowed us to test the effect of “ora-
cle-like” (i.e., with perfect a priori) knowledge of simulation scenario:
e.g., whether the two “int” models outperform other models in the
variable intercept, fixed slope scenario. In such cases, biomarker-
based coupling of slopes in the intercepts variation case (or vice versa)
is extraneous and may lead to spurious inference of group differences
if a model is allowed to infer coupling where none exists.
We compared biomarker coupled models to several simpler
coupled models. The simplest of these was the “OLS” model, an
uncoupled model which asymptotically corresponds to a Bayesian
model with a parameter covariance prior of α1I2n with α1 tending to
infinity (i.e., a high prior uncertainty on all parameters for all subjects).
The second model, “plain,” trades off fully independent and fully
coupled covariance priors, without any kernel-based coupling. It is
very similar to an LME model with random intercepts and random
slopes. To understand the role of kernel-based coupling, we compared
biomarker-kernel coupled models to random-information-kernel
coupled models. We formed a 200 × 1 vector r with each element
drawn from N(0, 1), so that each subject was assigned a random num-
ber, and formed another SE kernel K(r)SE based on it. We used this to
create “random,” parametrized exactly as “Gaussian both.” See Table 1
for further model details.
We compared our approach to standard LME modeling using the
LME implementation available in Freesurfer (Bernal-Rusiel et al.,
2013; Bernal-Rusiel, Reuter, Greve, Fischl, & Sabuncu, 2013).4 Specifi-
cally, we built two LME models, with fixed effects of baseline age and
baseline biomarker value and either random intercepts (termed “LME:
rI”) or random intercepts and slopes (“LME: rI, rS”).
We also compared our empirical Bayesian approach, which produces
point estimates of hyperparameter priors (i.e., an estimate of prior
means with zero variance) to a fully Bayesian approach, in which we
place priors on the hyperparameters and estimate their posterior distri-
bution. In this way, the fully Bayesian approach accounts for the hyper-
parameter uncertainty, which may improve parameter and prediction
coverage by improving the estimation of their uncertainties. We com-
pared the empirical Bayesian version of “plain,” with five covariance
hyperparameters (the α
0
s) and one inverse observation noise parameter
(β) to a fully Bayesian model with the same covariance structure. We
placed broad, uninformative half-normal priors on the α’s, by setting
each α~normal(0,100) with constraint α > 0, and an inverse Gamma dis-
tribution on β−1, setting β−1~InvGamma(1, 1). We used Markov chain
Monte Carlo (MCMC) to estimate the full model as it was no longer ana-
lytically tractable to derive all the necessary posterior distributions. We
implemented the full model in Stan (Carpenter et al., 2017) using Hamil-
tonian Monte Carlo. Due to the significantly longer running times of the
full model, (see Results) we ran the same two simulation scenarios for
50 instead of 200 subjects, with all other settings as before. We used
the default parameters for MCMC sampling: four chains, with 1,000
warm-up iterations and 1,000 sampling iterations per chain, so that the
posterior distributions had 4,000 sampling iterations in total. We
checked the convergence of the chains' posterior distributions using the
R metric provided. We checked the quality of the chain by looking at
the means, Markov chain standard errors (MCSE) and effective sample
sizes of the hyperparameters.
Finally, we performed additional simulations to test our assumption
of independent measurement noise, parameterized by β in Equation (6),
choosing five representative models in all cases: “Gaussian both” and
“plain” MTL models plus the two LME models and “OLS.” In the first set
of simulations, we varied the amount of within-subject noise correlation
by instead allowing a block diagonal noise structure. For each subject's
measurements, we used a noise covariance with σ2m =4 on the diagonal
and all off-diagonal terms set to ρσ2m, so that we recover uncorrelated
noise when ρ=0 and perfectly correlated noise (i.e., the same for all
observations over time) when ρ=1. We simulated with three levels of
ρ (0, 0.5, 0.75). In the second set of simulations used three levels of
3We do not vary the biomarker noise here as we found that, in general, it did not have a
strong effect on the models, particularly as compared to the measurement noise. 4https://surfer.nmr.mgh.harvard.edu/fswiki/LinearMixedEffectsModels.
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noise skewness: zero (Gaussian, as before), 0.6 (slightly skewed), and
0.9 (highly skewed), with σ2m =4 in all cases.
2.5 | Simulations: Model evaluation
Parametric Bayesian modeling provides probabilistic predictions (via
Equation [10]) and parameter distributions (via Equations (7)–(9)).
We can thus compare the performance of models in terms of both
their accuracy of predicting ground truth trajectories and how well
they estimate model parameters. The latter objective is potentially
important when there are group differences in trajectories, for
example, when a disease group has a steeper rate of gray matter
volume decline in a ROI compared to a healthy control group. In
such a case, using linear models we should be able to detect a dif-
ference in the slope parameters across the groups and, assuming the
decline starts from the same level, no corresponding difference in
intercepts.
For each model, we evaluated the mean absolute error (MAE) of
predicting subjects' held-out samples and quantified the accuracy of the
inferred trajectory parameters (intercepts and slopes) via coverage prob-
ability and MAE measures. We defined the coverage probability as the
fraction of times the true value of a parameter (intercept or slope) falls
within two standard deviations of its estimated value, that is, within the
posterior credible interval of the parameter. As this is a 95% credible
interval a coverage probability of 0.95 is an ideal outcome. For the
Bayesian MTL models, we can easily calculate these quantities using the
posterior means and variances (Equations (7)–(9)). For the LME mod-
els, direct estimates of the posterior parameter variance were not avail-
able: we therefore estimated them by adding the fixed effect and
random effect variance estimates of the intercept and slope when
appropriate.
In practice, the coverage probability may not be sufficient for
understanding how accurately a model estimates a parameter as a
model may simply estimate a high enough variance so that the true
value is always covered. For this reason, we also computed the error
(MAE) between the estimated parameters (intercept, slope) and their
known true values.
2.6 | ADNI application: Dataset
Data used in the preparation of this article were obtained from the
Alzheimer's disease neuroimaging initiative (ADNI) database (adni.
loni.usc.edu). The ADNI was launched in 2003 as a public–private
partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial
magnetic resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer's disease (AD). For
up-to-date information, see www.adni-info.org.
We used ADNI subjects with at least one [18F]-Florbetapir PET scan,
which images brain amyloid accumulation, using the earliest available
image as the baseline time-point. We chose a subset of 437 subjects:
104 cognitively normal (CN), 243 MCI, 90 probable Alzheimer's disease
(AD). Each had at least three MRIs at or after the chosen baseline, with a
total of 1,545 images across all subjects. There were 257 subjects with
three MRIs, 138 subjects with four MRIs, 31 subjects with five MRIs,
10 subjects with six MRIs and one subject with sevenMRIs.
We processed the PET scans to derive standardized uptake value
ratio (SUVR) values in cortical gray matter as measures of cortical
amyloid deposition at baseline, defined here as the first Florbetapir
scan available. Details of PET image processing can be found in Scelsi
et al. (2018). Briefly, tracer uptakes in the cortical ROI were standard-
ized to the uptake in a composite reference region following recom-
mendations from (Landau et al., 2015). We also used amyloid-β, total
tau and phosphorylated tau (pTau) from CSF measured at or before
baseline as measures of severity of amyloid and tau pathology. Lastly,
we retrieved subjects' apolipoprotein E (APOE) genetic information,
particularly the number of ε2 and ε4 alleles (Harold et al., 2009; Liu,
Kanekiyo, Xu, & Bu, 2013).
We parcellated the T1-weighted images using geodesic informa-
tion flows (GIF; Cardoso et al., 2015), creating 20 cortical sub-lobe
volumes from each image (see Figure S7 for the list of ROIs). We then
normalized each of these ROIs using each subject's total intracranial
volume (TIV). Normalized ROIs were subsequently used for longitudi-
nal trajectory modeling and out-of-sample prediction. We withheld
the final follow-up ROI from each model to test the out-of-sample
prediction accuracy of our models.
2.7 | ADNI application: Model building
We built eight different types of models, detailed in Table 2, for each
of the 20 regions for a total of 160 models.
We used first order (linear) polynomial models for all regions: previ-
ous work has shown this is a reasonable assumption for modeling corti-
cal trajectories (Ziegler et al., 2015). Based on our simulations (see
Results), we chose the “Gaussian both” type of model when using bio-
marker coupling, allowing both intercept and slope coupling, assuming
no prior knowledge of the type of coupling that exists in the data. We
formed four different kernels (K1, K2, K3, K4) based on true biomarkers
along with a fifth kernel based on a random biomarker-based kernel
(K5 = K(r)SE, r a vector of random values) as in the simulations. Kernels
Ki = K(bi)SE, i = 1, 2, 3 were formed using: (a) b1, a vector of SUVR values
across subjects derived from amyloid PET, (b) b2 = log(tau/Aβ), a vector
encoding the relationship between CSF tau, which increases in subjects
with AD, and CSF amyloid-β, which decreases in those with AD
(Sunderland et al., 2003), log transformed to improve normality, and
(c) b3, a vector encoding CSF pTau (Hampel et al., 2010).
To encode the APOE genetic similarity between subjects we used
the weighted identity by state (weighted-IBS) kernel function as in
Kwee et al., (Kwee, Liu, Lin, Ghosh, & Epstein, 2008):
kIBS, ij =
wε2IBSij,ε2 +wε4IBSij,ε4
wε2 +wε4
ð12Þ
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where the IBSij, ε2, IBSij, ε4 terms (each taking values 0, 1, or 2) refer to
the number of ε2 and ε4 alleles shared by subjects i and j. The inverse
minor allele frequency (1/MAF) weights wε2, wε4 serve to up-weight
rarer SNPs. The range of this function is between zero and two. To
better compare to the other SE kernels, we created an exponentiated
version of this kernel function:
kexpIBS,ij = exp −σ 2−kIBS, ij
   ð13Þ
that includes a scaling hyperparameter σ and has a range between
zero and one. We formed the K4 kernel matrix using this kernel
function.
We also compared our approach to (Freesurfer-based) LME
models. We built three LME models with fixed effects of age and
baseline amyloid load (measured via PET SUVR, as in the “PET amy-
loid” MTL model) and either random intercepts (termed “Rand Int”),
random intercepts and slopes (“Rand Int/Slp”) or random intercepts,
random slopes, and random amyloid (“Rand Int/Slp/Amyloid”).
3 | RESULTS
3.1 | Simulations: Results
Figure 2 depicts boxplots of the predictionMAEs across simulation runs.
Models using SE kernel-based coupling (“Gaussian” type models) gener-
ally performed better than their linear kernel counterparts (“linear” type
models). The advantage of the SE kernel in some cases may be attribut-
able to the ability to tune the kernel width (the σSE term) as an additional
hyperparameter,which adds scale flexibility. “Gaussian both”was consis-
tently among those with lowest MAE. We expected the oracle-like
models (“int” type in top row, “slope” type in bottom, markedwith aster-
isks in the figures) to outperform the other models, however, overall,
they perform similarly to the othermodels inmost cases. Importantly, all
MTLbasedmodels (including “plain”) outperform “OLS”bya largemargin,
roughly halving the error. Figure S1 depicts histograms of parameter
estimates for both “plain” and “OLS” for a representative simulation run,
showing that the Bayesianmodel shrinks both the slopes and intercepts
to their respective groupmean, decreasing the variance of the estimates
considerably. The shrinkage also results in a small increase in bias,
evidenced by the larger distance between the parameter means of
“plain” (dashed red line) to the true parameter means (dashed black line)
compared to “OLS” (dashed blue line), with an overall large decrease in
the mean squared errors of the parameter estimates (“plain”: 8.8 for
intercepts, 0.4 for slopes; “OLS”193.0 for intercepts, 8.1 for slopes).
The two LME models also performed well, with similar MAEs to the
“Gaussian” models. Figure S2 depicts the corresponding prediction cov-
erage probabilities, showing that both the MTL and LME models' pre-
dictions cover the true target value at close to the ideal rate of 0.95,
again outperforming “OLS” by a large margin, especially at higher noise
levels. We also observe that the simpler MTL models (“linear” models,
along with “plain”) have both high coverage in Figure S2 and relatively
high MAE in Figure 2, meaning that, compared to the other MTL and
LME models, they make relatively inaccurate predictions but estimate
high enough measurement uncertainty to cover the true target value.
Figure 3 depicts the corresponding parameter coverage probabili-
ties and estimation errors. In the fixed slope, varying intercepts sce-
nario (top row), coverage of the true fixed slope parameter was high
for all models (at or near 100%, exceeding the nominal level of 95%)
while intercept coverage varied greatly across models and noise
levels. The LME models generally did not cover the true intercept
values as frequently as the MTL models, particularly the random inter-
cepts model (“LME: rI”). The random intercepts, random slopes model
(“LME: rI, rS”) performed better at higher noise levels, but was gener-
ally outperformed by the MTL models. One possible explanation is
that the MTL models explicitly model parameter uncertainty as part of
their Bayesian formulation, while we have had to estimate the LME
models' overall parameter uncertainty by combining the associated
TABLE 2 Models fit for ADNI data
Model Purpose Kernel(s) Covariance prior # Cov. Hyper's
multiple Allow coupling via all four
true biomarkers
K1, K2, K3, K4 α1I2n +
P2
i = 1 αi1In + αi21n +
P4
j = 1 αi 2 + jð ÞKj
 
Mii 21
PET amyloid Allow coupling via SUVR similarity K1 = K(b1)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K1ð ÞMii 9
CSF tau/aBeta Allow coupling via tau/
aBeta similarity
K2 = K(b2)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K2ð ÞMii 9
CSF pTau Allow coupling via pTau similarity K3 = K(b3)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K3ð ÞMii 9
APOE Allow coupling via APOE ε2,
ε4 allele similarity
K4 = KexpIBS α1I2n +
P2
i = 1 αi1In + αi21n + αi3K4ð ÞMii 9
random Allow coupling via
random biomarker
K5 = K(r)SE α1I2n +
P2
i = 1 αi1In + αi21n + αi3K5ð ÞMii 9
plain No biomarker based
coupling
None α1I2n + (α11In + α121n)  M11 + (α21In + α221n)  M22 5
OLS No coupling None α1I2n, α1 ! ∞ 0
Note. Last column contains number of hyperparameters in given covariance prior.
AKSMAN ET AL. 3989
F
IG
U
R
E
2
B
o
xp
lo
ts
o
f
lo
g
m
ea
n
ab
so
lu
te
er
ro
rs
(M
A
E
s)
o
f
pr
ed
ic
ti
o
ns
o
f
al
lm
o
de
ls
ac
ro
ss
al
ls
im
ul
at
io
ns
ru
ns
fo
r
th
e
tw
o
sc
en
ar
io
s:
in
te
rc
ep
t
va
ri
at
io
n
(t
o
p
ro
w
)a
n
d
sl
o
p
e
va
ri
at
io
n
(b
o
tt
o
m
ro
w
)f
o
r
fo
ur
le
ve
ls
o
f
m
ea
su
re
m
en
t
no
is
e
(σ
m
).
M
o
de
ls
w
it
h
o
ra
cl
e-
lik
e
pr
io
r
in
fo
rm
at
io
n
ar
e
m
ar
ke
d
w
it
h
an
as
te
ri
sk
(t
o
p
ro
w
:"
in
t"
m
o
de
ls
;b
o
tt
o
m
ro
w
:"
sl
op
e"
m
o
d
el
s)
[C
o
lo
r
fi
gu
re
ca
n
b
e
vi
ew
ed
at
w
ile
yo
nl
in
el
ib
ra
ry
.c
o
m
]
3990 AKSMAN ET AL.
F
IG
U
R
E
3
B
o
xp
lo
ts
o
f
pa
ra
m
et
er
co
ve
ra
ge
pr
o
ba
bi
lit
ie
s
(i.
e.
,f
ra
ct
io
ns
o
f
ti
m
es
th
e
tr
ue
pa
ra
m
et
er
va
lu
e
fe
ll
w
it
hi
n
th
e
po
st
er
io
r
cr
ed
ib
le
re
gi
o
n)
an
d
lo
g
m
ea
n
ab
so
lu
te
er
ro
rs
(M
A
E
)b
et
w
ee
n
es
ti
m
at
ed
an
d
ac
tu
al
pa
ra
m
et
er
s
fo
r
th
e
tw
o
sc
en
ar
io
s:
in
te
rc
ep
t
va
ri
at
io
n
(t
o
p
ro
w
)a
nd
sl
o
pe
va
ri
at
io
n
(b
o
tt
o
m
ro
w
)f
o
r
fo
ur
m
ea
su
re
m
en
t
n
o
is
e
le
ve
ls
(σ
m
).
M
o
de
ls
w
it
h
o
ra
cl
e-
lik
e
pr
io
r
in
fo
rm
at
io
n
ar
e
m
ar
ke
d
w
it
h
an
as
te
ri
sk
(t
o
p
ro
w
:"
in
t"
m
o
de
ls
;b
o
tt
o
m
ro
w
:"
sl
op
e"
m
o
de
ls
)[
C
o
lo
r
fi
gu
re
ca
n
be
vi
ew
ed
at
w
ile
yo
nl
in
el
ib
ra
ry
.c
o
m
]
AKSMAN ET AL. 3991
fixed and random effect uncertainties. In addition, the LME models
also have higher parameter estimation errors (the intercept and slope
log MAE figures in the top row), which measures the quality of param-
eter mean estimates rather than variances. Overall in this scenario the
“Gaussian” models outperformed all others in terms of parameter cov-
erage and estimation error while the “linear” models and “plain” were
comparable to the LME models in terms of parameter estimation
error.
In the second scenario, fixed intercept and varying slopes
(Figure 3, bottom row), the “Gaussian” models performed well in both
parameter coverage and parameter estimation error; in this case, the
two LME models also performed competitively. “LME: rI, rS” had con-
sistently highest intercept and slope coverage and lowest parameter
estimation errors at low measurement noise levels, reflecting the fact
that the random slopes assumption is appropriate in this scenario.
However, this model's parameter estimation error, particularly the
slope MAE, increases sharply with higher measurement noise levels
while the “Gaussian” models are relatively unaffected.
The two simulation scenarios suggest that the “Gaussian” style
MTL models are a good choice for both prediction and parameter
inference and compare favorably with standard LME models in many
cases. Among these, “Gaussian both” is appealing, as it makes no a
priori assumptions on the type of coupling that exists within the data.
Therefore, we used this type of model throughout our experiments
with the Alzheimer's study data.
Figure S3, part A shows the empirical Bayesian implementation
of “plain” (“EB plain”) has very similar predictive performance to the
full Bayesian implementation (“MCMC plain”) in terms of prediction
error. Both have high coverage of the true target values though the
full Bayesian model is consistently closer to the optimal coverage of
0.95 while the empirical Bayesian model is prone to underestimating
the predictive uncertainty. Figure S3, part B depicts the parameter
estimation metrics: the full Bayesian model has much higher cover-
age of the intercept in both scenarios; both models have similarly
high coverage of the slope. The full Bayesian model has lower error
in estimating the true values of both intercepts and slopes in both
scenarios. We briefly compared the computation times of the two
F IGURE 4 Top: True and estimated annualized rates of change across cortex for four representative MTL models bottom: MAEs of
estimates. MAE, mean absolute error [Color figure can be viewed at wileyonlinelibrary.com]
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models on a single run of the intercept varying scenario with 20, 50,
and 100 subjects: the empirical Bayesian model took 0.13, 0.38, and
0.50 seconds, respectively, while the full Bayesian model was con-
siderably slower: 51,398 and 4,356 seconds, respectively. Table S1
gives the convergence diagnostics for the posterior estimates of the
hyperparameters of “MCMC plain” for one run of the intercept vary-
ing scenario. The estimates appear to have converged: all R values
were at their ideal values of one, the number of effective samples
(Neff) was high in all cases and the MCSE's were small compared to
the estimated posterior means, so that the 95% confidence intervals
on the means did not cross zero.
Figure S4 depicts results from the simulations that varied noise
correlation while Figure S5 depicts those with varied skewness. In
Figure S4, part A, we observe that the prediction related metrics are
similar between “Gaussian both” and the two LME models in both
simulations scenarios and that all models' prediction errors fall as
noise correlation increases. Figure S4, part B shows corresponding
parameter estimation metrics for both scenarios: “Gaussian both”
outperforms the LME models on intercept coverage and parameter
error in the intercept varying scenario (top row) but “LME: rI, rS” has
near optimal coverage in the slope varying scenario (bottom row),
where the random slopes assumption is appropriate. However,
these two models are similar in terms of slope coverage and both
intercept and slope estimation errors. Figure S5, part A depicts the
three different levels of measurement error skewness that we used
in the second set of simulations. In this case, we observe that vary-
ing skewness does not substantially affect any of the models' pre-
diction or parameter estimation metrics. Again, in general “Gaussian
both” and the two LME models have similar prediction coverages
and errors (part B), while “Gaussian both” outperforms the LME
models in parameter estimation in the intercepts varying scenario
(part C, top) and has similarly good performance in the slopes vary-
ing scenario (part C, bottom).
3.2 | ADNI application: Results
The likelihood term in Equation (6) assumes that observations are nor-
mally distributed about their mean (i.e., the residuals are normal) and
uncorrelated over time within each subject. We tested the impact of
these assumptions on ADNI modeling by comparing the histograms of
residuals for two models in Figure S6: “CSF tau/aBeta,” which was rep-
resentative of the biomarker-coupled MTL models, and “OLS,” the
uncoupled reference model. Across all regions, the residuals of “CSF
tau/aBeta” are much closer to being normally distributed that those of
“OLS.” We also tested for heteroscedasticity, calculating the correla-
tion of residuals to baseline age across subjects and found no signifi-
cant correlation in both models for any region.
Figure 4 (top part) depicts the true and estimated annualized rates
of change across the 20 cortical ROIs for four representative models
(“OLS,” “plain,” “random,” “multiple”). Note that there is no information
exchange between ROIs; in its presented form our method is univari-
ate, coupling across subjects within each ROI and modeling ROIs sep-
arately. We computed the true annualized rate of change by dividing
the percentage change from baseline to final (held-out) follow-up by
the number of elapsed years. We note that this true annualized rate is
essentially a two-point OLS estimate and is therefore more a silver
than a gold standard. We see most of the cortex degenerating by
0.33% (middle cingulate) to 1.3% (posterior insula) annually, with the
lateral regions generally degenerating faster than the medial regions
We computed the models' estimated annualized rates using their pre-
dictions of the held-out sample instead of the true held-out value.
Figure 4 (bottom) depicts the associated MAEs of these predictions,
with the three MTL models (“plain,” “random,” “multiple”) having lower
MAEs than the “OLS” model across most ROIs. The two kernel
coupled models (“random” and “multiple”) have further decreased
MAEs compared to “plain,” though there is no further discernible dif-
ference in MAE between the two.
F IGURE 5 Log Bayes factors across cortex, comparing each biomarker-coupled MTL model to “random” [Color figure can be viewed at
wileyonlinelibrary.com]
AKSMAN ET AL. 3993
Figure S7 provides a quantitative comparison of prediction error
across all OLS plus MTL models. We performed t-tests on the differ-
ence in absolute error between models to understand the effect of
various modeling choices, showing: (a) all MTL model errors are signif-
icantly lower than those of “OLS” across all ROIs bar the lateral tem-
poral region (where only "plain" and "random" have higher error than
“OLS”); (b) there is further improvement due to kernel coupling,
evidenced by significantly lower absolute errors in at least one model
relative to “plain” in 13 out of 20 ROIs; (c) as in simulations, there is a
small difference in error between random-information-based and
biomarker-based kernel coupling, with some biomarker-based models
having significantly lower error than “random” (within 10 ROIs: ante-
rior insula, DLPFC, lateral occipital, lateral parietal, lateral temporal,
medial parietal, medial temporal, posterior cingulate, supratemporal,
and temporal pole regions). Statistical tests were Bonferroni corrected
for 320 (eight models × 20 ROIs × 2 parameter types) comparisons.
Furthermore, Figure S8 depicts the MAEs of predicting annualized
rate of change for three LME models (described in Methods) built
using the same information as in “PET amyloid.” All models had very
similar MAEs across ROIs in this case.
Figure 5 depicts log Bayes factors across cortical regions for the
comparison of the five biomarker-coupled MTL models to “random,”
showing “CSF tau/aBeta,” “PET amyloid” and “multiple” have the largest
and most widespread improvements in model evidence. We also see
that “multiple” is most similar to “PET amyloid,” the best individual bio-
marker coupled model in terms of model evidence, providing some
assurance that combining kernels works as expected.
Figure 6 depicts the significance of diagnostic group differences (CN,
MCI, or AD) in subjects' estimated parameters across OLS, LME, and MTL
assessed via one-way analysis of variance (ANOVAs) and Bonferroni
corrected for 480 (12 model comparisons × 20 ROIs × 2 parameter
types) comparisons. The three models with highest model evidence are
depicted in Figure 6 (“CSF tau/aBeta,” “PET amyloid,” “multiple”); Figure S9
depicts all MTL models, with Bonferroni correction for 320 comparisons.
In both figures, cross-sectional differences in predicted volumes at mean
baseline age across subjects (73.5 years) are depicted instead of inter-
cepts. Intercepts represent group differences at age zero (i.e., at birth)
while we have measured and modeled cortical degeneration in older
adults. The three MTL models in Figure 6 agree that there are significant
cross-sectional disease-related differences in volumes across the cortex,
with sparing of the sensorimotor and cingulate regions (Figure 6, top
row). The three LME models, in contrast, detect a less widespread and
less significant pattern of cross-sectional differences than the MTL
models while "OLS" detects even fewer cross-sectional differences.
Longitudinally, the bottom row of Figure 6 shows both “Rand Int”
and “Rand Int/Slp” have almost no significant slope differences in any
region, while “Rand Int/Slp/Amyloid” detects some significant differ-
ences within parts of the temporal lobe, insula and parietal regions,
F IGURE 6 Top: Significance of (cross-sectional) diagnostic group differences in predicted volume at mean baseline age (73.5 years) for OLS,
LME, and selected MTL models bottom: same for (longitudinal) group differences in estimated slopes [Color figure can be viewed at
wileyonlinelibrary.com]
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but does not detect the expected slope difference within the medial
temporal lobe. The three MTL models, including “PET amyloid,” which
represents the fairest comparison to the LME models, have significant
differences across the temporal lobe (including the medial temporal
lobe), insula, orbitofrontal region and, in the case of “multiple,” the lat-
eral parietal region. Overall the MTL models infer a more plausible
pattern of both cross-sectional and longitudinal disease effects than
standard LME models.
It is reassuring that similar types of biological coupling (amyloid load
measured via CSF and PET in “CSF tau/aBeta” and “PET amyloid” respec-
tively) result in similar patterns of longitudinal differences. The longitudi-
nal differences in the lateral parietal region detected by “multiple” may
be due to its incorporation of all biomarker coupling priors: “APOE” and
“CSF ptau” also show some differences within that region (Figure S9,
bottom row). In contrast to these biomarker-coupled models, “random”
does not detect any significant slope differences while “OLS” detects
few cross-sectional differences; neither model is plausible given other
studies of AD-related atrophy (Frisoni, Fox, Jack, Scheltens, & Thomp-
son, 2010; Risacher et al., 2010; Ziegler et al., 2015).
Interestingly, “plain” only detects longitudinal differences within the
medial temporal and temporal pole, suggesting that while this model can
reliably detect strong true effects (see simulations), it may not be as sen-
sitive as models with additional prior information. Further to this,
Figure S10 depicts data for two regions: the medial temporal region,
where most models agree that there are both cross-sectional and longi-
tudinal differences, and the lateral temporal region, where “plain”
detects no longitudinal differences, though they are clearly evident in
the figure. We further observe that “APOE” detects a similar though
weaker pattern of longitudinal differences compared to the other bio-
marker coupled models, suggesting that coupling based on similarity of
genetic AD risk, conferred at birth, is less informative than coupling
based on levels of amyloid accumulated decades later in older adults.
We also tested for cortical differences in subjects with differing num-
bers of APOE ε4 alleles (either 0, 1, or 2), analyzing each diagnostic group
separately. Figure S11 depicts group differences in number of alleles for
“APOE,” “PET amyloid,” and “multiple.” “OLS,” “plain,” and “random”
showed no differences in neither baseline volumes nor slopes (data not
shown) while “CSF ptau” and “CSF tau/aBeta” (not shown) had spatial pat-
terns resembling that of “PET amyloid,” which shows allele-related differ-
ences in temporo-parieto-frontal, insular and anterior cingulate regions
within the MCI group. There is a more widespread pattern of slope dif-
ferences in “APOE” and “multiple” which is consistent with Ziegler et al.
(2015), who found slope differences within temporo-parieto-frontal cor-
tical gray matter in stable MCI subjects. However, these models also find
slope differences within the insula and anterior cingulate in MCI subjects
that were not reported in that study.
4 | DISCUSSION
We have presented a multi-task learning based approach to modeling
individuals' longitudinal biomarker trajectories, setting the learning of
each trajectory as a “task” and using flexible covariance priors to
couple tasks (i.e., subjects) during model training. Thanks to its para-
metric Bayesian formulation, our approach makes probabilistic predic-
tions, infers distributions over parameters and allows for the
comparison of competing models via model evidence. Using empirical
Bayes (rather than time-consuming cross-validation), we showed how
we can combine (a) fully decoupled models (i.e., individual-specific tra-
jectory models; OLS-like); (b) fully coupled models (i.e., a common tra-
jectory across subjects; LME-like); and (c) models coupled via one or
more biomarker-based similarity matrices (i.e., kernels). In this way,
our approach uses multi-kernel learning and capitalizes on different
aspects of biology measured by different biomarkers, within a multi-
task learning framework.
We performed simulations of trajectories having group wise varia-
tions in intercept and slope, showing that even the simplest version of
our proposed model (“plain,” mixing decoupled and fully coupled
models) dramatically outperforms decoupled models (“OLS”) in terms
of predictive accuracy. We achieved further reductions in prediction
error by adding kernel-based coupling using both random information
and biomarkers (in various configurations, with and without oracle-like
knowledge of simulation scenario). Interestingly, random-information-
based kernels performed almost as well as the biomarker-based ker-
nels (Figure 2), though the biomarker-based models (“Gaussian both”
and the oracle-like models of each scenario) had better inference of
true group differences (Figure 3). As such, biomarker-based models
are the better choice for accurately making predictions and inferring
parameters. We further conclude that “Gaussian both,” which allows
biomarker-based coupling in all parameter types (e.g., intercepts and
slopes) is a better choice than “linear both” in terms of predictive per-
formance and parameter inference. We emphasize the importance of
parameter inference for both scientific (e.g., model interpretation) and
translational purposes (e.g., trajectory parameter-based biomarkers
such as ROI rates of change).
In this article, we used empirical Bayes to estimate the coupling
and noise hyperparameters, leading to a point estimate of the prior
values of these variables. However, the full Bayesian approach may
better account for both parameter and predictive uncertainty by plac-
ing priors on hyperparameters and estimating their posterior distribu-
tions. In our simulations, the two approaches had similar prediction
errors and coverages. The models differed more in their parameter
estimates: full Bayes had better parameter coverage and lower param-
eter error in some cases. On the other hand, empirical Bayes' gradient
descent based hyperparameter optimization runs significantly faster
and scales better with the number of tasks than full Bayes' MCMC
sampling, thus providing a critical advantage of EB over full Bayes in
real world applications. It is important to note though that in cases
where the necessary posteriors can be derived, Gibbs sampling can
significantly reduce this computational burden, making full Bayes
more appealing (see for example, Huertas et al., 2017).
We tested the assumption of independent measurement noise,
parameterized by β in Equation (6), with additional simulations. In gen-
eral, prediction and parameter estimation errors were similar to or
lower than LME models across varying noise correlations (Figure S4).
However, some degradation of parameter coverage was evident,
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particularly at the highest noise correlation level, suggesting that a
more general parameterization of the measurement error covariance
(e.g., a block diagonal form allowing within-subject correlation) may be
necessary in some situations. We also explored the effect of non-
Gaussian distributed measurement error, finding that in general both
the MTL and LME models were robust to error skewness in terms of
both predictions and parameter estimates (Figure S5).
We applied the model to longitudinal data from the ADNI study,
modeling trajectories of cortical ROIs across CN, MCI, and AD sub-
jects using kernels formed from amyloid PET, CSF, and genetic
(APOE) information. We showed degeneration throughout the cortex,
with lateral regions degenerating faster than medial regions (Figure 4).
We showed significantly decreased prediction errors due to coupling
(“plain” vs. “OLS”) and further decreases when adding kernel-based
coupling, with a small difference between the random-information
versus biomarker coupled models in some ROIs (Figures 4 and S7).
Our model offers improved interpretability and more concrete biologi-
cal explanations of trajectory differences across diagnostic groups com-
pared to the baseline models. Here, we were mainly interested in
understanding how cortical degeneration varies across diagnostic groups,
which required that we carefully interpret the patterns of group differ-
ences (Figures 6 and S9). Single biomarker models based on either “PET
amyloid” or “CSF tau/aBeta” had cross-sectional and longitudinal group dif-
ferences that were consistent with the literature and had the most evi-
dence in their favor (Figure 5). Importantly, this analysis showed the
benefit in coupling cortical trajectories based on baseline measures of
amyloid deposition measured via PET or amyloid-to-tau ratio via CSF,
which is consistent with the prevailing disease progression model of AD in
which amyloid deposition precedes change in brain structure (Jack et al.,
2010). Coupling based on genetic risk for AD as realized by the APOE
genotype was inferior to using baseline amyloid-based biomarkers. This
agrees with the literature in that APOE genotype is the genetic risk and
amyloid biomarker levels represent the realization of that risk. Further-
more, we showed that combining multiple kernels is effective in the sense
that “multiple,” the multi-modal model, was as good as the best individual
model in terms of model evidence and parameter inference. Thus, our
approach removes the requirement to pre-select any specific biomarker.
All coupled models had significant diagnostic group differences
across the cortex at mean baseline age, agreeing with the pattern of
later-stage neurofibrillary changes due to AD that have been shown
to be detectable via MRI (Braak & Braak, 1991; Whitwell et al., 2008),
along with many of the AD discrimination studies that have used
cross-sectional structural MRI based features (Arbabshirani, Plis,
Sui, & Calhoun, 2016). In particular, the pattern of cross-sectional dif-
ferences we find aligns with Karas et al., (Karas et al., 2003), which
reported AD-related differences within the temporal lobe and insula,
with sparing of the sensorimotor cortex. We also found no significant
differences within the motor and sensory ROIs, supporting the idea
that sensorimotor function is relatively spared in AD, unless the dis-
ease is very advanced (Ferreri et al., 2016; Suvà et al., 1999). Among
the models with high model evidence in their favor, namely “CSF
tau/aBeta,” “PET amyloid,” and “multiple,” there were significant longi-
tudinal (i.e., slope) differences within the temporal lobe, orbitofrontal
region, insula and lateral parietal region. These findings are similar to
the patterns of group differences in 1 year atrophy depicted in
Risacher et al. (2010), although the authors did not focus on their
apparent findings within the insula. Insel et al. (2015) identified
changes within the insula and temporal regions occurring prior to the
clinical threshold for amyloid-β positivity, and interestingly, we detect
longitudinal differences in these regions with models that couple
based on similarity of protein measures.
In addition to clinical diagnosis, we also investigated the effect of
APOE ε4, the major genetic risk factor for late-onset AD, analyzing
differences in subjects grouped by number of ε4 alleles (Figure S11).
We found no cross-sectional volume differences at mean baseline age
within each group and few significant longitudinal differences within
the CN and AD groups. The CN finding is consistent with the litera-
ture: Filippini et al. (2009) found no volumetric differences within the
brain between young, healthy ε4 carriers and matched non-carriers
using cross-sectional information while Raz et al. (2010) found no dif-
ferences due to ε4 within healthy middle-aged and older adults using
longitudinal data. Our findings indicate similar homogeneity within AD
subjects. Within the MCI group we found a temporo-parietal–frontal
pattern of slope differences that aligned with previous literature
(Ziegler et al., 2015) along with additional slope differences with the
insula and anterior cingulate. We note that the findings within this
group may be due to both the larger sample size and greater hetero-
geneity of the MCI group compared to the CN and AD groups.
We also compared our novel MTL approach to a widely available
LME implementation, showing that MTL makes very similar prediction
errors on the held-out ADNI follow-ups (Figure S8). However, MTL
detected more widespread cross-sectional group differences than the
three LME models we considered and, importantly, more significant
longitudinal differences within the temporal lobe (Figure 6). As such
the MTL based parameters appear to be more plausible than the LME
based parameters. Additionally, our method automatically finds the
covariance structure that best explains the training data (within the
limit of the chosen parameterization), removing modeling decisions
such as whether a variable is or is not a random effect.
The approach we have presented has several limitations, however.
Firstly, computing the log marginal likelihood at each optimization
step involves the inversion of the prior covariance matrix (see Appen-
dix), which scales cubically with the number of subjects in the worst
case. This precludes coupling beyond hundreds of subjects and
restricts us to univariate modeling. A multivariate approach would
exacerbate the problem, scaling cubically with the product of subjects
by variables. Reduced rank approaches or inducing point methods
may speed up computation, as would a diagonal approximation of the
matrix inversions, sacrificing accuracy for speed. Alternatively, one
could use GPUs; Tensorflow has highly optimized linear algebra rou-
tines for matrix operations that can deliver an order of magnitude
speed improvements (Abadi et al., 2016). Secondly, beyond computa-
tional considerations, our model may not capture long term, nonlinear
trends that are only evident across subjects (see for example, Donohue
et al., 2014). To properly model these may require adding a fixed
effects component to accommodate higher-order polynomial functions
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describing group-level trajectories. Alternatively, one may switch to
modeling trajectories of study time, which may introduce significant
intercept differences.
There are multiple directions for future work. As mentioned in the
introduction, the method we present is not a disease progression
model and as such it does not estimate a disease stage for each sub-
ject. It does, however, provide plausible estimates of trajectory param-
eters, which may serve as valuable inputs to a staging model. Future
work will investigate the staging of subjects based on these parame-
ters within an EBM (Young et al., 2014), providing insight into the role
of brain structural changes during the progression from normal cogni-
tion to Alzheimer's disease (Jack et al., 2010). We can also extend our
understanding of the relationship between genetics and cortical atro-
phy beyond APOE to all single nucleotide polymorphisms (SNPs) using
multivariate methods such as partial least squares (PLS; Lorenzi et al.,
2018) or canonical correlation analysis (Szefer, Lu, Nathoo, Beg, &
Graham, 2017). Finally, we can generalize the approach to simulta-
neously model multiple variables across subjects (i.e., multi-output
learning), where interesting modeling possibilities (coupling parame-
ters across variables within and between subjects) and computational
challenges abound. It is important to note that benefits of such an
approach depend on whether there are strong multivariate relation-
ships that can be modeled through either correlated parameters or
errors. For example, Marinescu et al., (2019) show that there are
widespread patterns in neurodegenerative disease progression that
can be modeled via spatial coupling, while earlier studies showed only
a modest benefit of this type of coupling relative to the computational
effort involved (Marquand, Brammer, et al., 2014a; Marquand,
Brammer, et al., 2014; Zhang & Shen, 2012).
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APPENDIX
We wish to find the hyperparameters that maximize the model's mar-
ginal likelihood. For computational and analytic reasons, it is easier to
minimize the negative (natural) log marginal likelihood, setting this as
the optimizer's objective. We need the partial derivatives with respect
to each hyperparameter, constraining each to be strictly positive. For
the noise term β this is a natural constraint; for the coupling weights α
we follow the rule that a positive sum of valid kernels is also a valid
kernel. To impose these constraints within an unconstrained optimizer
we transform the variables, optimizing log(β) and log(α), which will be
strictly positive when exponentiated. To derive the necessary partial
derivatives with respect to the transformed variables we make use of
the chain rule:
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∂ log yjα,βð Þ
∂ log βð Þ =
∂ log yjα,βð Þ
∂β
∂β
∂ log βð Þ =
∂ log yjα,βð Þ
∂β
β
=
m
2
−
β
2
yTy + βyTXm+ β2yTXb−
β
2
mTXTXm−β2bTXTXm
−βbTΣ αð Þ−1priorm−
β
2
tr A−1XTX
 
∂ log yjα,βð Þ
∂ log αið Þ =
∂ log yjα,βð Þ
∂αi
∂αi
∂ log αið Þ =
∂ log yjα,βð Þ
∂αi
αi
where αi is an element within vector α, b = (Ind − βA−1XTX)A−1XTy and
∂ log yjα,βð Þ
∂αi
= −
1
2
tr Σ αð Þ−1prior
∂Σ αð Þprior
∂αi
	 

−
1
2
tr A−1F
 
+ βyTXc−βcTXTXm−cTΣ αð Þ−1priorm−
1
2
mTFm
F=
∂Σ αð Þ−1prior
∂αi
= −Σ αð Þ−1prior
∂Σ αð Þprior
∂αi
Σ αð Þ−1prior
c= −βA−1FA−1XTy
and the ∂Σ(α)prior/∂αi depends on the αi in question. We can easily change
the parameterization of Σ(α)prior without breaking these equations, pro-
vided it remains invertible and differentiable with respect to its parameters.
For the form used in Equations (3)–(5), we need ∂Σ(α)prior/∂α1 = Ind,
∂Σ(α)prior/∂αi1 = In  Mii, ∂Σ(α)prior/∂αi2 = 1n  Mii and ∂Σ(α)prior/∂αi(j + 2)
= Kj  Mii for thematrix weighting hyperparameters, where i = 1, … , d and
j = 1, … , k. Some kernels may also have internal hyperparameters (also
included in α); one such example is the σSE parameter of the SE kernel. In
this case, we need ∂Σ(α)prior/∂σSE = − αi(j + 2)(D  Kj)  Mii where
Kj = exp(−σSED) and is the element-wise product.
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